DS-1 (drug)

DS-1 is a drug from the imidazopyridine family, which is the first drug developed that acts as a GABAA receptor positive allosteric modulator (PAM) selective for the α4β3δ subtype, which is not targeted by other GABAA receptor PAMs such as the benzodiazepines or other nonbenzodiazepine drugs. Novel selective drugs such as DS-1 should prove useful in the study of this receptor subtype.[1]

DS-1
Identifiers
IUPAC name
  • 4-chloro-N-(6,8-dibromo-2-thiophen-2-ylimidazo[1,2-a]pyridin-3-yl)benzamide
CAS Number
PubChem CID
IUPHAR/BPS
ChemSpider
CompTox Dashboard (EPA)
ECHA InfoCard100.209.966
Chemical and physical data
FormulaC18H10Br2ClN3OS
Molar mass511.62 g·mol−1
3D model (JSmol)
SMILES
  • s4cccc4-c2nc1c(Br)cc(Br)cn1c2NC(=O)c(cc3)ccc3Cl
  (verify)

See also

References
  1. Wafford KA, van Niel MB, Ma QP, Horridge E, Herd MB, Peden DR, et al. (January 2009). "Novel compounds selectively enhance delta subunit containing GABA A receptors and increase tonic currents in thalamus". Neuropharmacology. 56 (1): 182–9. doi:10.1016/j.neuropharm.2008.08.004. PMID 18762200. S2CID 207224202.
This article is issued from Wikipedia. The text is licensed under Creative Commons - Attribution - Sharealike. Additional terms may apply for the media files.